Cost Effectiveness Of Linezolid In Central America
- Registration Number
- NCT01040585
- Lead Sponsor
- Pfizer
- Brief Summary
The therapy with Linezolid (LIN) represents better cost-effectiveness vs. Vancomycin (VAN) for the treatment of nosocomial Pneumonia associate to ventilator (VAP).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Evidence of a legally acceptable representative signed and dated informed consent document indicating that him or her has been informed of all pertinent aspects of the study.
- Adult (18 years old or older) men and women with confirm diagnosis of VAP treated on ICU with LIN or VAN; on the selected institutions.
Exclusion Criteria
- Adult men or women with nosocomial pneumonia not associated to a ventilator.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Central America and the Caribbean Linezolid Panama, Costa Rica, Honduras, El Salvador and Nicaragua
- Primary Outcome Measures
Name Time Method The rate of resistance Empirical treatment days before specific therapy. Treatment days with Linezolid. Treatment days with Vancomycin. 4 months Rate of renal failure. 4 months Rate of healing with Linezolid. 4 months Rate of healing with Vancomycin. 4 months
- Secondary Outcome Measures
Name Time Method Hospitalization days average with VAN and Linezolid. 4 months Variation of prices and values among the different institutions. 4 months The average costs of each intervention. 4 months